- Home
- ZBAI vs KZIA Comparison
ZBAI vs KZIA Comparison
Compare ZBAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- KZIA
- Stock Information
- Founded
- ZBAI 2015
- KZIA 1994
- Country
- ZBAI United States
- KZIA Australia
- Employees
- ZBAI N/A
- KZIA N/A
- Industry
- ZBAI Professional Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAI Consumer Discretionary
- KZIA Health Care
- Exchange
- ZBAI Nasdaq
- KZIA Nasdaq
- Market Cap
- ZBAI 11.3M
- KZIA 11.7M
- IPO Year
- ZBAI N/A
- KZIA 1999
- Fundamental
- Price
- ZBAI $8.62
- KZIA $7.69
- Analyst Decision
- ZBAI
- KZIA Strong Buy
- Analyst Count
- ZBAI 0
- KZIA 3
- Target Price
- ZBAI N/A
- KZIA $16.00
- AVG Volume (30 Days)
- ZBAI 90.7K
- KZIA 236.4K
- Earning Date
- ZBAI 12-18-2025
- KZIA 11-14-2025
- Dividend Yield
- ZBAI N/A
- KZIA N/A
- EPS Growth
- ZBAI N/A
- KZIA N/A
- EPS
- ZBAI N/A
- KZIA N/A
- Revenue
- ZBAI $720,000.00
- KZIA $1,549,158.00
- Revenue This Year
- ZBAI N/A
- KZIA N/A
- Revenue Next Year
- ZBAI N/A
- KZIA N/A
- P/E Ratio
- ZBAI N/A
- KZIA N/A
- Revenue Growth
- ZBAI 44.00
- KZIA 248983.08
- 52 Week Low
- ZBAI $4.83
- KZIA $2.86
- 52 Week High
- ZBAI $45.00
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- ZBAI 51.71
- KZIA 57.99
- Support Level
- ZBAI $7.98
- KZIA $6.51
- Resistance Level
- ZBAI $8.96
- KZIA $7.39
- Average True Range (ATR)
- ZBAI 0.73
- KZIA 0.42
- MACD
- ZBAI -0.14
- KZIA 0.09
- Stochastic Oscillator
- ZBAI 32.34
- KZIA 86.21
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.